instrument_fundamentals
| date | Close | change | Change (%) | instr__open | High | Low |
|---|
instr__news
Is It Time To Reassess Sartorius (XTRA:SRT3) After Extended Share Price Weakness?
Ensuring reliable PFAS analysis
Sartorius (XTRA:SRT3) Valuation Check As Recent Weakness Contrasts With Rich P/E And DCF Upside
Kepler Capital Keeps Their Hold Rating on Sartorius (0NIR) | Markets Insider
Sartorius launches next-generation platform to boost efficiency in cell therapy production
RBC Capital Sticks to Their Hold Rating for Sartorius (0NIR) | Markets Insider
Analyzing Sonova (OTCMKTS:SONVY) & Sartorius (OTCMKTS:SARTF) - Markets Daily
Kepler Capital Sticks to Its Hold Rating for Sartorius (0NIR) | Markets Insider
Assessing Sartorius (XTRA:SRT3) Valuation As Viral Vaccine Media Demand Gains Attention
Sartorius (XTRA:SRT3) Valuation Check After 2025 Earnings Show Higher Sales And Net Income
Is Sartorius (XTRA:SRT3) Now Pricing In A Recovery After Recent Sector Sentiment Shifts
